Let's get physical: Improving the medical care of people with severe mental illness

Advances in Psychiatric Treatment

Volumn 18, Issue 3, 2012, Pages 216-225

  Mitchell, Alex J ^a,b   Delaffon, Vijay ^c   Lord, Oliver ^a  

^a LEICESTERSHIRE PARTNERSHIP NHS TRUST   (United Kingdom)

^b UNIVERSITY OF LEICESTER   (United Kingdom)

^c LEICESTER GENERAL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; ANTICOAGULANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; HEMOGLOBIN A1C; LIPID; NEUROLEPTIC AGENT;

BLOOD PRESSURE MONITORING; DEPRESSION; DYSLIPIDEMIA; GENERAL PRACTITIONER; GLUCOSE BLOOD LEVEL; HEALTH CARE PERSONNEL; HEALTH CARE PLANNING; HEALTH CARE QUALITY; HEALTH PRACTITIONER; HUMAN; LIPOPROTEIN BLOOD LEVEL; MEDICAID; MEDICAL CARE; MENTAL DISEASE; METABOLIC DISORDER; OSTEOPOROSIS; PREVENTIVE MEDICINE; REVIEW; SCHIZOPHRENIA; SMOKING CESSATION;

EID: 84861181186     PISSN: 13555146     EISSN: 14721481     Source Type: Journal    
DOI: 10.1192/apt.bp.111.009068     Document Type: Review

References (103)

1. Alaja R, Seppa K, Sillanaukee P, et al (1998) Physical and mental comorbidity of substance use disorders in psychiatric consultations. Alcoholism - Clinical and Experimental Research 22: 1820-4. (Pubitemid 28536178)
2. Álvarez-Jiménez M, Hetrick SE, González-Blanch C, et al (2008) Non-pharmacological management of antipsychotic-induced weight gain: systematic review and meta-analysis of randomised controlled trials. British Journal of Psychiatry 193: 101-7.
3. Amati A, Biondi M, Bogetto F, et al (2006) Sindrome metabolica e patologi correlate nella schizofrenia: linee guida per il monitoraggio medico [Metabolic syndrome and related conditions in schizophrenia: guidelines for medical monitoring]. Giornale Italiano di Psicopatologia 12 (suppl 1): 5-14.
4. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, et al (2004) Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 27: 596-601.
5. Banta JE, Morrato EH, Lee SW, et al (2009) Retrospective analysis of diabetes care in California Medicaid patients with mental illness. Journal of General Internal Medicine 24: 802-8.
6. Barnett AH, Mackin P, Chaudhry I, et al (2007) Minimising metabolic and cardiovascular risk in schizophrenia: diabetes, obesity and dyslipidaemia. Journal of Psychopharmacology 21: 357-73. (Pubitemid 47077296)
7. Baune BT, Adrian I, Jacobi F (2007) Medical disorders affect health outcome and general functioning depending on comorbid major depression in the general population. Journal of Psychosomatic Research 62: 109-18. (Pubitemid 46161593)
8. Bell RC, Farmer S, Ries R, et al (2009) Metabolic risk factors among Medicaid outpatients with schizophrenia receiving second-generation antipsychotics. Psychiatric Services 60: 1686-9.
9. Bernardo M, Cañas F, Banegas JR, et al (2009) Prevalence and awareness of cardiovascular risk factors in patients with schizophrenia: A crosssectional study in a low cardiovascular disease risk geographical area. European Psychiatry 24: 431-41.
10. Berren MR, Santiago JM, Zent MR, et al (1999) Health care utilization by persons with severe and persistent mental illness. Psychiatric Services 50: 559-61. (Pubitemid 29165799)
11. Bobes J, Alegría AA, Saiz-Gonzalez MD, et al (2011) Change in psychiatrists' attitudes towards the physical health care of patients with schizophrenia coinciding with the dissemination of the consensus on physical health in patients with schizophrenia. European Psychiatry 26: 305-12.
12. Bresee LC, Majumdar SR, Patten SB, et al (2010) Prevalence of cardiovascular risk factors and disease in people with schizophrenia: a population-based study. Schizophrenia Research 117: 75-82.
13. Cabana MD, Rand CS, Powe NR, et al (1999) Why don't physicians follow clinical practice guidelines? A framework for improvement. JAMA 282: 1458-65. (Pubitemid 29493800)
14. Cahn W, Ramlal D, Bruggeman R, et al (2008) Preventie en behandeling van somatische complicaties bij antipsychoticagebruik [Prevention and treatment of somatic complications arising from the use of antipsychotics]. Tijdschrift voor Psychiatrie 50: 579-91.
15. Chiu CC, Chen CH, Chen BY, et al (2010) The time-dependent change of insulin secretion in schizophrenic patients treated with olanzapine. Progress in Neuro-Psychopharmacology & Biological Psychiatry 34: 866-70.
16. Colton CW, Manderscheid RW (2006) Congruencies in increased mortality rates, years of potential life lost, and causes of death among public mental health clients in eight states. Preventing Chronic Disease 3: A42.
17. Copeland LA, Zeber JE, Pugh MJ, et al (2008) Postoperative complications in the seriously mentally ill: A systematic review of the literature. Annals of Surgery 248: 31-8.
18. Correll CU, Harris JL, Pantaleon Moya RA, et al (2007) Low-density lipoprotein cholesterol in patients treated with atypical antipsychotics: missed targets and lost opportunities. Schizophrenia Research 92: 103-7. (Pubitemid 46561219)
19. Daumit GL, Crum RM, Guallas E, et al (2002) Receipt of preventive medical services at psychiatric visits by patients with severe mental illness. Psychiatric Services 53: 884-7. (Pubitemid 34742774)
20. De Hert M, Falissard B, Mauri M, et al (2008) Epidemiological study for the evaluation of metabolic disorders in patients with schizophrenia: the METEOR study. European Neuropsychopharmacology 18 (suppl 4): s444.
21. De Hert M, Dekker JM, Wood D, et al (2009) Cardiovascular disease and diabetes is people with severe mental illness position statement from the European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiology (ESC). European Psychiatry 4: 412-24.
22. De Hert M, Vancampfort D, Correll CU, et al (2011) Guidelines for screening and monitoring of cardiometabolic risk in schizophrenia: systematic evaluation. British Journal of Psychiatry 199: 99-105.
23. Dembling BP, Chen DT, Vachon L (1999) Life expectancy and causes of death in a population treated for serious mental illness. Psychiatric Services 50: 1036-42. (Pubitemid 29365365)
24. De Nayer A, De Hert M, Scheen A, et al (2005) Belgian consensus on metabolic problems associated with atypical antipsychotics. International Journal of Psychiatry in Clinical Practice 9: 130-7. (Pubitemid 40874109)
25. Department of Health (1999) National Service Framework for Mental Health. Modern Standards and Service Models. TSO (The Stationery Office).
26. Desai MM, Rosenheck RA (2005) Unmet need for medical care among homeless adults with serious mental illness. General Hospital Psychiatry 27: 418-25. (Pubitemid 41566068)
27. Desai MM, Rosenheck RA, Druss BG, et al (2002) Mental disorders and quality of diabetes care in the veterans health administration. American Journal of Psychiatry 159: 1584-90. (Pubitemid 35006741)
28. Dinan T, Holt R, Kohen D, et al (2004) 'Schizophrenia and Diabetes 2003' Expert Consensus Meeting, Dublin, 3-4 October 2003: consensus summary. British Journal of Psychiatry 184 (suppl 47): s112-4. (Pubitemid 38482554)
29. Druss BG, von Esenwein SA, Compton MT, et al (2010a) A randomized trial of medical care management for community mental health settings: The Primary Care Access, Referral, and Evaluation (PCARE) study. American Journal of Psychiatry 167: 151-9.
30. Druss BG, Zhao L, von Esenwein SA, et al (2010b) The Health and Recovery Peer (HARP) program: a peer-led intervention to improve medical self-management for persons with serious mental illness. Schizophrenia Research 118: 264-70.
31. Elkis H, Gama C, Suplicy H, et al (2008) Consenso Brasileiro sobre antipsicóticos de segunda geração e distúrbios metabólicos [Brazilian consensus on second-generation antipsychotics and metabolic disorders]. Revista Brasileira de Psiquiatria 30: 77-85. (Pubitemid 351508004)
32. Fisher WH, Barreira PJ, Geller JL, et al (2001) Longstay psychiatric patients in state hospitals at the end of the 20th century. Psychiatric Services 52: 1051-6. (Pubitemid 32757996)
33. Forsner T, Hansson J, Brommels M, et al (2010) Implementing clinical guidelines in psychiatry: a qualitative study of perceived facilitators and barriers. BMC Psychiatry 10: 8.
34. Francke AL, Smit MC, de Veer AJ, et al (2008) Factors influencing the implementation of clinical guidelines for health care professionals: a systematic meta-review. BMC Medical Informatics and Decision Making 8: 38.
35. Gabriele JM, Dubbert PM, Reeves RR (2009) Efficacy of behavioural interventions in managing atypical antipsychotic weight gain. Obesity Reviews 10: 442-55.
36. Goodwin JS, Zhang DD, Ostir GV (2004) Effect of depression on diagnosis, treatment, and survival of older women with breast cancer. Journal of the American Geriatrics Society 52: 106-11. (Pubitemid 38090398)
37. Gothefors D, Adolfsson R, Attvall S, et al (2010) Swedish clinical guidelines - prevention and management of metabolic risk in patients with severe psychiatric disorders. Nordic Journal of Psychiatry 64: 294-302.
38. Graber M, Bergus G, Dawson J, et al (2000) Effect of a patient's psychiatric history on physicians' estimation of probability of disease. Journal of General Internal Medicine 15: 204-6. (Pubitemid 30155355)
39. Grol R (2001) Success and failures in the implementation of evidence-based guidelines for clinical practice. Medical Care 39: 1146-54.
40. Harris EC, Barraclough B (1998) Excess mortality of mental disorder. British Journal of Psychiatry 173: 11-53. (Pubitemid 28312203)
41. Hewer W, Salize HJ, Wolfersdorf M (2004) Umfrage zur Qualität der internistischen Versorgung in psychiatrischen Fachkrankenhäusern] [Quality of care in internal medicine in German psychiatric hospitals]. Psychiatrische Praxis 31: 404-8. (Pubitemid 39656880)
42. Himelhoch S, Daumit G (2003) To whom do psychiatrists offer smoking-cessation counseling? American Journal of Psychiatry 160: 2228-30. (Pubitemid 39619618)
43. Hippisley-Cox J, Parker C, Coupland C, et al (2007) Inequalities in the primary care of patients with coronary heart disease and serious mental health problems: a cross-sectional study. Heart 93: 1256-62. (Pubitemid 47492915)
44. Holt RIG, Pendlebury J, Wildgust HJ, et al (2010) Intentional weight loss in overweight and obese patients with severe mental illness: 8-year experience of a behavioral treatment program. Journal Of Clinical Psychiatry 71: 800-5.
45. Horvitz-Lennon M, Kilbourne AM, Pincus HA (2006) From silos to bridges: meeting the general health care needs of adults with severe mental illnesses. Health Affairs 25: 659-69. (Pubitemid 43824915)
46. Jamie G (2012) QOF indicators for 2013-14. QOF News 28 January (http://news.gpcontract.co.uk).
47. Jones LE, Carney CP (2005) Mental disorders and revascularization procedures in a commercially insured sample. Psychosomatic Medicine: 67: 568-76. (Pubitemid 41033585)
48. Kaplowitz RA, Scranton RE, Gagnon DR, et al (2006) Health care utilization and receipt of cholesterol testing by veterans with and those without mental illness. General Hospital Psychiatry 28: 137-44. (Pubitemid 43324676)
49. Khaykin E, Ford DE, Pronovost PJ, et al (2010) National estimates of adverse events during nonpsychiatric hospitalizations for persons with schizophrenia. General Hospital Psychiatry 32: 419-25.
50. Kim MM, Swanson JW, Swartz MS, et al (2007) Healthcare barriers among severely mentally ill homeless adults: evidence from the five-site health and risk study. Administration and Policy in Mental Health and Mental Health Services Research 34: 363-75. (Pubitemid 46742605)
51. Lambert TJR, Chapman LH (2004) Diabetes, psychotic disorders and antipsychotic therapy: a consensus statement. Medical Journal of Australia 181: 544-8. (Pubitemid 39545630)
52. Lambert T, Newcomer J (2009) Are the cardiometabolic complications of schizophrenia still neglected? Barriers to care. Medical Journal of Australia 190: s39-42.
53. Lefebvre N, Chereau I, Schmitt A, et al (2006) Comorbidités somatiques chez les patients souffrant de schizophrénie traitée. Recommandations actuelles [Comobid somatic conditions in patients with treated schizophrenia. Current recommendations]. Annales Medico-Psychologiques 164: 159-64.
54. Leucht S, Burkard T, Henderson J, et al (2007) Physical illness and schizophrenia: a review of the literature. Acta Psychiatrica Scandinavica 116: 317-33. (Pubitemid 47537428)
55. Lord O, Malone D, Mitchell AJ (2010) Receipt of preventive medical care and medical screening for patients with mental illness: a comparative analysis. General Hospital Psychiatry 32: 519-43.
56. Lowe T, Lubos E (2008) Effectiveness of weight management interventions for people with serious mental illness who receive treatment with atypical antipsychotic medications. A literature review. Journal of Psychiatric and Mental Health Nursing 15: 857-63.
57. Mangtani P, Breeze E, Kovats S, et al (2005) Inequalities in influenza vaccine uptake among people aged over 74 years in Britain. Preventive Medicine 41: 545-53. (Pubitemid 40732370)
58. Marder SR, Essock SM, Miller AL, et al (2004) Physical health monitoring of patients with schizophrenia. American Journal of Psychiatry 161: 1334-49. (Pubitemid 38989085)
59. McDonald D, Frakes M, Apostolidis B, et al (2003) Effect of a psychiatric diagnosis on nursing care for nonpsychiatric problems. Research in Nursing & Health 26: 225-32. (Pubitemid 38622724)
60. McEvoy JP, Meyer JM, Goff DC, et al (2005) Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophrenia Research 80:19-32. (Pubitemid 41587460)
61. McIntyre JS, Romano J (1977) Is there a stethoscope in the house (and is it used)? Archives of General Psychiatry 34: 1147-51. (Pubitemid 8216725)
62. Melkersson KI, Dahl M-L, Hulting A-L (2004) Guidelines for prevention and treatment of adverse effects of antipsychotic drugs on glucose-insulin homeostasis and lipid metabolism. Psychopharmacology 175: 1-6. (Pubitemid 39215524)
63. Millar HL (2010) Development of a health screening clinic. European Psychiatry 25: s29-33.
64. Mitchell AJ, Malone D (2006) Physical health and schizophrenia. Current Opinion in Psychiatry 19: 432-7. (Pubitemid 44317873)
65. Mitchell AJ (2009a) Do antipsychotics cost lives or save lives? Risks versus benefits from large epidemiological studies. Journal of Clinical Psychopharmacology 29: 517-9.
66. Mitchell AJ, Malone D, Doebbeling CC (2009b) Quality of medical care for people with and without comorbid mental illness and substance misuse: systematic review of comparative studies. British Journal of Psychiatry 194: 491-9.
67. Mitchell AJ, Lord O (2010) Do deficits in cardiac care influence high mortality rates in schizophrenia? A systematic review and pooled analysis. Journal of Psychopharmacology 24: 69-80.
68. Mitchell AJ, Delaffon V, Vancampfort D, et al (2012) Guideline concordant monitoring of metabolic risk in people treated with antipsychotic medication: systematic review and meta-analysis of screening practices. Psychological Medicine 42: 125-47.
69. Nasrallah HA, Meyer JM, Goff DC, et al (2006) Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: data from the CATIE schizophrenia trial sample at baseline. Schizophrenia Research 86: 15-22. (Pubitemid 44234064)
70. National Alliance on Mental Illness (2008) Schizophrenia: Public Attitudes, Personal Needs: Views from People Living with Schizophrenia, Caregivers, and the General Public. NAMI.
71. National Collaborating Centre for Mental Health (2010) Schizophrenia: The NICE Guideline on Core Interventions in the Treatment and Management of Schizophrenia in Adults in Primary and Secondary Care - Updated Edition (CG82). British Psychological Society & Royal College of Psychiatrists.
72. National Institute for Health and Clinical Excellence (2011) About the Quality and Outcomes Framework (QOF). NICE (http://www.nice.org.uk/ aboutnice/qof/qof.jsp).
73. Neeleman J (2001) A continuum of premature death. Meta-analysis of competing mortality in the psychosocially vulnerable. International Journal of Epidemiology 30: 154-62.
74. Newcomer JW (2005) Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs 19: 1-93.
75. Organ B, Nicholson E, Castle D (2010) Implementing a physical health strategy in a mental health service. Australasian Psychiatry 18: 456-9.
76. Parks J, Svendsen D, Singer P, et al (2006) Morbidity and Mortality in People with Serious Mental Illness. National Association of State Mental Health Program Directors (NASMHPD) Medical Directors Council.
77. Paton C, Esop R, Young C, et al (2004) Obesity, dyslipidaemias and smoking in an inpatient population treated with antipsychotic drugs. Acta Psychiatrica Scandinavica 110: 299-305. (Pubitemid 39278989)
78. Patterson CW (1978) Psychiatrists and physical examinations: a survey. American Journal of Psychiatry 135: 967-8.
79. Pincus HA (2010) From PORT to policy to patient outcomes: crossing the quality chasm. Schizophrenia Bulletin 36: 109-11.
80. Pincus HA, Page AEK, Druss B, et al (2007) Can psychiatry cross the quality chasm? Improving the quality of health care for mental and substance use conditions. American Journal of Psychiatry 164: 712-9. (Pubitemid 46808523)
81. Poulin M-J, Cortese L, Williams R, et al (2005) Atypical antipsychotics in psychiatric practice: practical implications for clinical monitoring. Canadian Journal of Psychiatry 50: 555-62. (Pubitemid 43161788)
82. Price JH, Ambrosetti LM, Sidani JE, et al (2007) Psychiatrists' smoking cessation activities with Ohio community mental health center patients. Community Mental Health Journal 43: 251-66. (Pubitemid 46897312)
83. Roberts L, Roalfe A, Wilson S, et al (2007) Physical health care of patients with schizophrenia in primary care: a comparative study. Family Practice 24: 34-40. (Pubitemid 46454663)
84. Rubin AS, Littenberg B, Ross R, et al (2005) Effects on processes and costs of care associated with the addition of an internist to an inpatient psychiatry team. Psychiatric Services 56: 463-7. (Pubitemid 40471590)
85. Rummel-Kluge C, Komossa K, Schwarz S, et al (2010) Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis. Schizophrenia Research 123: 225-33.
86. Ryan R, Sunada K (1997) Medical evaluation of persons with mental retardation referred for psychiatric assessment. General Hospital Psychiatry 19: 274-80. (Pubitemid 27400828)
87. Saha S, Chant D, McGrath J (2007) A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time? Archives of General Psychiatry 64: 1123-31. (Pubitemid 47529346)
88. Saiz JR, Bobes GJ, Vallejo JR, et al (2008) Consensus on physical health of patients with schizophrenia from the Spanish Societies of Psychiatry and Biological Psychiatry. Actas Españolas de Psiquiatría 36: 251-64.
89. Salokangas RKR, Hirvonen J, Honkonen T, et al (2008) Schizophrenia treatment guideline update. Duodecim S1-22.
90. Salsberry PJ, Chipps E, Kennedy C (2005) Use of general medical services among Medicaid patients with severe and persistent mental illness. Psychiatric Services 56: 458-62. (Pubitemid 40471589)
91. Saravane D, Feve B, Frances Y, et al (2009) Élaboration de recommandations pour le suivi somatique des patients atteints de pathologie mentale sévère [Drawing up guidelines for the attendance of physical health of patients with severe mental illness]. L'Encéphale 251: 1-10.
92. Sheldon TA, Cullum N, Dawson D, et al (2004) What's the evidence that NICE guidance has been implemented? Results from a national evaluation using time series analysis, audit of patients' notes and interviews. BMJ 329: 999-1004.
93. Stein MB, Cox BJ, Afifi TO, et al (2006) Does co-morbid depressive illness magnify the impact of chronic physical illness? A population-based perspective. Psychological Medicine 36: 587-96.
94. Tarricone I, Gozzi BF, Serretti A, et al (2010) Weight gain in antipsychoticnaive patients: a review and meta-analysis. Psychological Medicine 40: 187-200.
95. Taylor D, Young C, Mohamed R, et al (2005) Undiagnosed impaired fasting glucose and diabetes mellitus amongst inpatients receiving antipsychotic drugs. Journal of Psychopharmacology 19: 182-6. (Pubitemid 40577223)
96. Tosh G, Clifton A, Mala S, et al (2010) Physical health care monitoring for people with serious mental illness. Cochrane Database of Systematic Reviews (issue 3): CD008298.
97. Tsoi DT, Porwal M, Webster AC (2010) Interventions for smoking cessation and reduction in individuals with schizophrenia. Cochrane Database of Systematic Reviews (issue 6): CD007253.
98. Unützer J, Schoenbaum M, Druss BG, et al (2006) Transforming mental health care at the interface with general medicine: Report for the President's Commission. Psychiatric Services 57: 37-47. (Pubitemid 43053835)
99. US Department of Health and Human Services (1999) Mental Health: A Report of the Surgeon General - Executive Summary. US Department of Health and Human Services, Substance Abuse and Mental Health Services Administration, Center for Mental Health Services, National Institutes of Health, National Institute of Mental Health.
100. Usher K, Foster K, Park T (2006) The metabolic syndrome and schizophrenia: the latest evidence and nursing guidelines for management. Journal of Psychiatric and Mental Health Nursing 13: 730-4. (Pubitemid 44706032)
101. Verdoux H, Boulon S, Cougnard A (2008) Gender differences in metabolic monitoring of second-generation antipsychotic prescriptions. Human Psychopharmacology Clinical and Experimental 23: 471-4.
102. Werneke U, Horn O, Maryon-Davis A, et al (2006) Uptake of screening for breast cancer in patients with mental health problems. Journal of Epidemiology and Community Health 60: 600-5. (Pubitemid 44032822)
103. Whyte S, Penny C, Phelan M, et al (2007) Quality of diabetes care in patients with schizophrenia and bipolar disorder: cross-sectional study. Diabetic Medicine 24: 1442-8. (Pubitemid 350179455)